

CASE REPORT

Campylobacter jejuni and *Pseudomonas* coinfection in the setting of ulcerative colitis

John Paul Iguidbashian,¹ Jai D Parekh,² Shweta Kukrety,² Venkata Giri Andukuri²¹CHI Health Creighton University Medical Center Bergan Mercy, Omaha, Nebraska, USA²Internal Medicine, CHI Health Creighton University Medical Center Bergan Mercy, Omaha, Nebraska, USA**Correspondence to**
Dr Jai D Parekh,
jai.d.parekh@gmail.com

Accepted 18 May 2018

SUMMARY

A 66-year-old woman presented with 2 days of fever and severe diarrhoea. She has a history of ulcerative colitis (UC), well controlled with medication. She also has a history of Ehlers-Danlos syndrome, infective endocarditis following aortic valve replacement and pulmonary embolism. She had complained of passing stool with traces of blood about 30 times per day. Stool testing for *Clostridium difficile*, routine culture and microscopy was done. She was started on ceftriaxone. CT scan revealed thick-walled colon consistent with UC flare. Flexible sigmoidoscopy showed active continuous colitis extending from the rectum to the proximal descending colon. *Campylobacter jejuni* was isolated from the stool and blood cultures yielded *Pseudomonas aeruginosa*. The antibiotic was transitioned to intravenous piperacillin/tazobactam and azithromycin followed by 2 weeks of intravenous cefepime. Her diarrhoea was controlled, and she was discharged for follow-up in 2 months.

BACKGROUND

This case demonstrates several important learning points when working up a case of gastrointestinal (GI) infection in the context of underlying inflammatory bowel disease (IBD). First, it is necessary to test the stool for GI pathogens even if uncomplicated IBD flare is suspected. In this case, initial work-up pointed towards ulcerative colitis (UC) flare as the primary source of her symptoms, as the CT demonstrated inflamed colonic walls and *Clostridium difficile* testing was negative. However, on further testing the stool was found positive for *Campylobacter jejuni* infection. Another interesting finding in this case was the presence of *Pseudomonas aeruginosa* bacteraemia as a coinfection leading to the worsening clinical picture in our patient. It is rare to have different organisms infecting the colon and the bloodstream simultaneously. This work-up was crucial to the management as our patient was switched to appropriate antibiotic coverage before her symptoms started to improve.

CASE PRESENTATION

A 66-year-old woman presented with 2 days of fever and severe diarrhoea. She reported having around 30 foul-smelling bowel movements per day with minimal blood noted in the stool. She had no other symptoms including nausea, vomiting, focal weakness, chest pain or shortness of breath. The patient had a history of UC well controlled with balsalazide and had not had a UC flare for nearly 15 years;

however, she stated that this current episode did feel like her typical UC exacerbation. Other medical history included Ehlers-Danlos syndrome, infective endocarditis following aortic valve replacement and pulmonary embolism. She had no significant family history and did not use tobacco or alcohol. Physical examination was unremarkable except for mild tenderness in the lower quadrants of the abdomen.

INVESTIGATIONS

CT abdomen with contrast showed hyperenhancing thick-walled colon, consistent with UC flare (Figure 1). Flexible sigmoidoscopy showed congested, erythematous, granular and vascular pattern with decreased mucosa starting in the rectum and extending to the descending colon. *C. difficile* testing by PCR was negative. Stool cultures came back positive on the second day of admission for *C. jejuni* identified via Gram stain, catalase, oxidase and hippurate testing and blood cultures came back positive for *P. aeruginosa* the following day. Antibiotic sensitivity was also performed at this time.

DIFFERENTIAL DIAGNOSIS

1. UC flare.
2. *C. difficile* infection.
3. Infective colitis.
4. Other GI pathogen infection.

TREATMENT

The patient was empirically started on ceftriaxone while infectious work-up was being completed. Once the stool and blood culture results were available, she was transitioned to intravenous piperacillin/tazobactam and azithromycin to provide coverage for both *C. jejuni* and *P. aeruginosa*. Symptoms began to improve, and she was sent home on a 2-week course of intravenous cefepime.

OUTCOME AND FOLLOW-UP

Our patient's symptoms decreased significantly in the hospital. She was having less than five bowel movements per day and her abdominal pain was minimal. The patient was discharged home once her oral intake was adequate and her strength began to improve. She finished her course of antibiotics at home and will have a follow-up colonoscopy in 2 months as an outpatient.

DISCUSSION

Intestinal super-infections may occur in the setting of IBD, complicating the clinical picture and



To cite: Iguidbashian JP, Parekh JD, Kukrety S, et al. *BMJ Case Rep* Published Online First: [please include Day Month Year]. doi:10.1136/bcr-2018-224941




Figure 1 Coronal CT abdomen with contrast demonstrating thickened colonic wall (white arrows) suggestive of ulcerative colitis.

triggering flares of disease. The IBDs, Crohn's disease and UC, are T-cell-mediated diseases that are characterised by chronic, relapsing inflammation of the intestinal tract. The pathogenesis of IBD involves the complex interaction between the intestinal micro-flora, host genetic and immune factors, and environmental stimuli. Epidemiological analyses have implicated acute bacterial enteritis as one of the factors that may incite or exacerbate IBD in susceptible individuals.¹

Quondamcarlo *et al* reported a case of *C. jejuni* enterocolitis in a 19-year-old woman and their difficulty in distinguishing IBD from atypical infectious colitis. It highlighted the importance of ruling out GI pathogen infection when assessing IBDs at onset and during flare-ups, especially if corticosteroids or immunosuppressive therapies are required. After an unsuccessful course of corticosteroids, ceftazidime and metronidazole, the patient was successfully treated with erythromycin.² Seigal *et al* reported a case of *C. jejuni* pan-colitis mimicking idiopathic UC in a 91-year-old woman. The patient was eventually treated with a 7-day course of moxifloxacin.³ Topic *et al* described a case of polymicrobial *Actinomyces naeslundii* and *P. aeruginosa* sepsis in a patient with a previously silent abdominal actinomycosis, developed 2 months after colonoscopy when the diagnosis of a left-sided UC was established. The patient was successfully treated with a course of high-dose ceftriaxone.⁴

A few cases have described *C. jejuni* and other GI pathogens in association with underlying UC.⁵ It is well documented that IBD is a significant risk factor for a variety of GI infections, and this is likely what happened to our patient.^{6,7} Numerous cases report IBD flares creating an opportunistic environment for infection.

The unique aspect of this case is the coexisting *P. aeruginosa* bacteraemia, which has only been reported in association with UC a few times.^{8,9} In addition, in the setting of IBD there has not been a reported case of differing organisms in the stool and in the bloodstream. This demonstrates the importance of testing blood cultures even after identifying the GI pathogen. The identification of two different pathogens helped us choose appropriate antibiotic therapy, which resulted in clinical improvement of the patient.

Learning points

- ▶ Consider underlying infection in the setting of ulcerative colitis flare, especially when patient's inflammatory bowel disease (IBD) has previously been well controlled.
- ▶ Consider multiorganism coinfection when working up gastrointestinal infection in the setting of underlying IBD.
- ▶ Identify specific organisms in order to treat with appropriate antibiotic coverage.

Contributors JPI provided and cared for the patient, outlined and wrote the case report, and coordinated involvement of all authors. JDP provided and cared for the patient, reviewed and revised written report, and acted as corresponding author for the project. SK provided and cared for the patient, contributed background information, and reviewed and revised the written report. VGA cared for the patient and served as scientific adviser for the project.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient consent Obtained.

Provenance and peer review Not commissioned; externally peer reviewed.

© BMJ Publishing Group Ltd (unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

REFERENCES

- 1 Kalischuk LD, Buret AG. A role for *Campylobacter jejuni*-induced enteritis in inflammatory bowel disease? *Am J Physiol Gastrointest Liver Physiol* 2010;298:G1–G9.
- 2 Quondamcarlo C, Valentini G, Ruggeri M, *et al*. *Campylobacter jejuni* enterocolitis presenting as inflammatory bowel disease. *Tech Coloproctol* 2003;7:173–7.
- 3 Siegal D, Syed F, Hamid N, *et al*. *Campylobacter jejuni* pan-colitis mimicking idiopathic ulcerative colitis. *Heart Lung* 2005;34:288–90.
- 4 Topic MB, Desnica B, Vicković N, *et al*. The polymicrobial *actinomyces naeslundii* and *pseudomonas aeruginosa* sepsis in a patient with ulcerative colitis 2 months after colonoscopy. *Wien Klin Wochenschr* 2014;126:130–2.
- 5 Arora Z, Mukewar S, Wu X, *et al*. Risk factors and clinical implication of superimposed *Campylobacter jejuni* infection in patients with underlying ulcerative colitis. *Gastroenterol Rep* 2016;4:287–92 <https://academic.oup.com/gastro/article/4/4/287/2568569>.
- 6 Hilbert F, Scherwitzel M, Paulsen P, *et al*. Survival of *Campylobacter jejuni* under conditions of atmospheric oxygen tension with the support of *Pseudomonas* spp. *Appl Environ Microbiol* 2010;76:5911–7 <https://www.ncbi.nlm.nih.gov/pubmed/20639377>.
- 7 Nagasaki A, Takahashi H, Iinuma M, *et al*. Ulcerative colitis with multidrug-resistant *Pseudomonas aeruginosa* infection successfully treated with bifidobacterium. *Digestion* 2010;81:204–5 <https://www.ncbi.nlm.nih.gov/pubmed/20090336>.
- 8 Jessica AH, Faten A, Joanne L, *et al*. Inflammatory bowel disease and *Aeromonas* infection: a commensal or an initiating or a causative agent? *The American J of Gastroenterology* 2003;98:S174 <https://www.nature.com/articles/ajg20031169>.
- 9 Lobatón T, Hoffman I, Vermeire S, *et al*. *Aeromonas* species: an opportunistic enteropathogen in patients with inflammatory bowel diseases? A single center cohort study. *Inflamm Bowel Dis* 2015;21:71–8 <https://www.ncbi.nlm.nih.gov/pubmed/25517595>.

Copyright 2018 BMJ Publishing Group. All rights reserved. For permission to reuse any of this content visit <http://group.bmj.com/group/rights-licensing/permissions>.

BMJ Case Report Fellows may re-use this article for personal use and teaching without any further permission.

Become a Fellow of BMJ Case Reports today and you can:

- ▶ Submit as many cases as you like
- ▶ Enjoy fast sympathetic peer review and rapid publication of accepted articles
- ▶ Access all the published articles
- ▶ Re-use any of the published material for personal use and teaching without further permission

For information on Institutional Fellowships contact consortiasales@bmjgroup.com

Visit casereports.bmj.com for more articles like this and to become a Fellow